Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma

H. J. Close*, †, L. F. Stead*, †, J. Nsengimana*, K. A. Reilly*, A. Droop**, †, H. Wurdak*, †, R. K. Mathew*, ‡, R. Corns, ‡, J. Newton-Bishop*, A. A. Melcher*, ‡, S. C. Short*, † and E. B. Wilson*, †

*Leeds Institute of Medical Research at St James's, University of Leeds School of Medicine, St James's University Hospital, Leeds, UK, †MRC Medical Bioinformatics Centre, University of Leeds, ‡Department of Neurosurgery, Leeds General Infirmary, Leeds, and §Institute of Cancer Research, London.

Summary

Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed as weakly immunogenic, GBM responds poorly to current immunotherapies. To understand this problem more clearly we used a combination of natural killer (NK) cell functional assays together with gene and protein expression profiling to define the NK cell response to GBM and explore immunosuppression in the GBM microenvironment. In addition, we used transcriptome data from patient cohorts to classify GBM according to immunological profiles. We show that glioma stem-like cells, a source of post-treatment tumour recurrence, express multiple immunomodulatory cell surface molecules and are targeted in preference to normal neural progenitor cells by natural killer (NK) cells ex vivo. In contrast, GBM-infiltrating NK cells express reduced levels of activation receptors within the tumour microenvironment, with hallmarks of transforming growth factor (TGF)-β-mediated inhibition. This NK cell inhibition is accompanied by expression of multiple immune checkpoint molecules on T cells. Single-cell transcriptomics demonstrated that both tumour and haematopoietic-derived cells in GBM express multiple, diverse mediators of immune evasion. Despite this, immunome analysis across a patient cohort identifies a spectrum of immunological activity in GBM, with active immunity marked by co-expression of immune effector molecules and feedback inhibitory mechanisms. Our data show that GBM is recognized by the immune system but that anti-tumour immunity is restrained by multiple immunosuppressive pathways, some of which operate in the healthy brain. The presence of immune activity in a subset of patients suggests that these patients will more probably benefit from combination immunotherapies directed against multiple immunosuppressive pathways.

Keywords: glioblastoma, immune-inhibition, NK cells

Introduction

Glioblastoma (GBM) is the most common and aggressive type of primary adult brain cancer. Current treatments include debulking neurosurgery and adjuvant chemo/radiotherapy. Despite these therapies, median overall survival is just 12–24 months [1]. Recent developments in cancer immunotherapy provide one potential approach to improve patient outcomes [2]. However, despite significant therapeutic impact on several solid tumour types, immune checkpoint blockade (ICB) is yet to demonstrate benefit in GBM treatment [3].

Evasion of host immunity is a hallmark of cancer [4]. Tumours exploit the negative feedback mechanisms that the healthy immune system uses to dampen immune responses. These mechanisms include the recruitment of immune cells with suppressive activity, the expression of immunosuppressive cytokines, such as transforming growth factor (TGF)-β and immune checkpoints, including programmed cell death (PD)-1 and cytotoxic T lymphocyte antigen (CTLA)-4 [5]. Chronic interactions between tumour cells and infiltrating T cells leads to an exhausted phenotype, an unresponsive but reversible state with an altered transcriptional profile [6]. Exhausted tumour-infiltrating
lymphocytes express immune checkpoints, and antibodies that target these molecules can reinvigorate anti-tumour immunity [7].

Mutations in the tumour genome are a source of neoantigens and mutation frequency is a surrogate marker for immunogenicity [8]. For several tumours, neoantigen load is correlated with survival and with response to immune checkpoint blockade; melanoma and lung adenocarcinoma have higher mutational load, greater T cell infiltration, greater PD-1 expression and consequently show better responses to anti-PD-1 therapy [9]. Compared to other solid tumours, mutation frequency and T cell infiltration levels in GBM are low. However, GBM-infiltrating T cells have been isolated against a number of germline-encoded antigens over-expressed in the tumour, indicating that T cell responses are at least possible [10]. Glioblastoma cells are a target for natural killer (NK) cells; however, the number of GBM-infiltrating natural killer (NK) cells is also low [11]. The paucity of NK cells and T cells in GBM is compounded by the high proportion of suppressive myeloid-lineage cells [12] able to suppress lymphocyte function [5].

Importantly, GBM-infiltrating T cells express PD-1 [13], yet reports of initial anti-PD-1 (nivolumab) clinical trials are not encouraging [2]. This indicates that PD-1 expression per se is not sufficient to allow responsiveness to therapy, and that additional suppressive components of the GBM immune landscape regulate many effectors of anti-tumour immunity.

Here we show that, in vitro, GBM cells are recognized and killed by NK cells; however, NK cells derived from GBM tumours have an altered cell surface phenotype consistent with their inhibition in the tumour microenvironment. We have explored the basis of this inhibition and identify numerous immunosuppressive mechanisms operating in GBM contributed by both tumour and immune cell compartments. These immunosuppressive pathways, some of which appear to operate in the normal brain, are a barrier to effective immunotherapy, but also represent candidate therapeutic targets to reinvigorate tumour NK cell interactions.

Materials and methods

Ethics statement

Ethical approval for this study was granted by the ethics committee at the Leeds Teaching Hospitals NHS Trust, Leeds UK (REC number 10-H1306-7).

Classification of GBM patients consensus immune cluster (CIC)

CIC classification [14] was applied to GBM tumour transcriptome data from The Cancer Genome Atlas (TCGA). Briefly, consensus cluster analysis of melanomas used the expression of 380 genes specific to 24 immune cell types ([15]; this produced six subtypes which we termed CICs. The average expression of each gene within each CIC is the cluster centroid. Using TCGA data, we used the nearest centroid method [16] to classify each GBM tumour into one of the CICs according to the highest Spearman’s correlation coefficient with the centroids. For each of the 24 immune cell types of the immunome compendium [15], we calculated a score per GBM tumour, graphically represented using a heatmap.

Differential expression of genes in GBM CIC2 and CIC4 and in REMBRANDT data

To compare the expression of selected genes in different patient groups we used RNAseq data from TCGA [obtained via The Cancer Imaging Archive (TCIA) [7]], assigning patients to either CIC2 or CIC4 (as above). In addition, we used microarray data from the REMBRANDT study [17] downloaded from Betastasis.com. For REMBRANDT, patient samples were classified as granzyme A (GZMA)\textsuperscript{high} expressors or GZMA\textsuperscript{low} expressors based on the median expression value (\(n = 214\)). Expression of selected genes was compared between CIC2 and CIC4 (for TCGA data) or the GZMA\textsuperscript{high} and GZMA\textsuperscript{low} patients (for REMBRANDT) and analysed using non-parametric, unpaired statistical testing (using GraphPad Prism).

Single-cell data and normal brain analysis

Single-cell (sc)RNAseq data were downloaded from [18] and expression of candidate genes analysed. Data were visualized using rStudio version 1.0.143 (package: gplots 3.0.1) using heatmap.2. Untransformed data clustering (unsupervised) was performed (Euclidean distance). Individual cells were classified as ‘tumour’ or ‘immune’ according to co-expression of SRY-box transcription factor 9 (SOX9) and epidermal growth factor receptor (EGFR) [18] and protein tyrosine phosphatase receptor type C (PTPRC), respectively. For all genes, expression of > 0 was scored positive. For immune (PTPRC\textsuperscript{+}) and tumour (SOX9\textsuperscript{+}EGFR\textsuperscript{+}) cells, the number of different immunomodulatory molecules expressed was counted for each cell and the percentage of immune and non-immune cells expressing immunomodulatory genes plotted. Expression of individual genes in non-tumour-bearing brain tissue was downloaded from [19]. These data are also available (with graphical output) at BrainRNAseq.org.

Tumour tissue and blood, collection and processing

After ethical approval and informed consent, tumours were resected and stored in phosphate-buffered saline (PBS) or within the cavitron ultrasonic surgical aspirator (CUSA) [20]. Samples were washed in PBS, CUSA samples were prepared as shown by Schroeteler et al. [20] and all
samples were filtered through a 40-µm cell strainer, washed twice in PBS, centrifuged at 400 g for 5 min and resuspended in PBS, 0.5% bovine serum albumin (BSA) and 0.05% sodium azide. Matched patient blood was diluted with PBS, layered over Ficoll (Axis-Shield PoC, Oslo, Norway) and centrifuged at 800 g for 20 min. Tumour and blood-derived cells were stained with appropriate antibodies and isotype controls (see Supporting information, Table S1), with single stain controls on tumour samples used for compensation during analysis using the cytoexpert compensation matrix. All samples were run on a CytoFlex S (Beckman Coulter Life Sciences, Indianapolis, IN, USA) (see Supporting information, Table S1). Gated, isotype control stained, intratumoral or peripheral blood NK cells from each patient (Supporting information, Fig. S1) were assigned a gate of 2% positive, and specific antibody staining is reported within this gate.

Primary cells and cell lines

Neural progenitor cells (NP1) were isolated from a patient undergoing surgery to treat epilepsy [21]. The primary lines, GBM1 and NP1, were generated at the Scripps Institute. GBM11, GBM13 and GBM20 were derived at the University of Leeds using the same method and culture conditions [22]. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of healthy donors as above. NK cells were further separated using an NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 10% human AB serum (Sigma-Aldrich, Gillingham, UK).

Surface antigen screening

GBM stem-like cell (GSC) lines were harvested using 0.25% trypsin/ethylenediamine tetraacetic acid (EDTA) and fluorescently labelled for 60 min at 37°C and 5% CO2 in serum-free media with one of the the following cell dyes: 0.4 µM cell trackerTM (CT)-green CMFDA (488 nm excitation), 2 µM CTorange-CMRA (488 nm excitation), 2 µM CTviolet-BMQC (407 nm excitation) or 5 µM calcine blue-AM (407 nm excitation) (all from Invitrogen, Carlsbad, CA, USA). All populations were washed three times, mixed together and plated at a density of 1 × 10^6 total cells/well in 96-well round-bottomed plates (Nunc, Roskilde, Denmark). Cells were stained as per the manufacturer’s instructions with 242 antibodies from the BD Bioscience Lyoplate screening panel, followed by Zombie NIR (Biolegend, San Diego, CA, USA) for 30 min before resuspension and analysis by flow cytometry. Cells were gated based on their emitting fluorescence at 520 nm (CTgreen loaded), 580 nm (CTorange loaded), 540 nm (CTviolet loaded) or 449 nm (calcine blue loaded). The median fluorescence intensity (MFI) for each gated population, for each antigen and isotype control emission at 668 nm (Alexa647 emission) was generated and GSC lines scored as positive if more than 20% of the population expressed the antigen. Flow cytometry and settings are as described earlier; analysis was performed using FacsDivia (BD Biosciences, San Jose, CA, USA), FlowJo (Treestar, Inc., Ashland, OR, USA) and Kaluza (Beckman Coulter) software.

Natural killer cytotoxicity assays

Target tumour cell lines were labelled with the relevant cell dye (see surface screen) for 1 h at 37°C, washed twice and plated at 2 × 10^5/well. NK cells were pre-activated with 20 ng/ml interleukin (IL)-15 for 48 h and mixed with targets at the E : T ratios indicated. After 5 h, cells were pelleted (300 g for 5 min), washed with PBS and stained with Zombie NIR (Biolegend) for 15 min at room temperature. Competitive cytotoxicity assays were set up as above; the two target cell types under test (GBM and neural progenitors) were labelled with either CTgreen or CTviolet, mixed 1 : 1 and used as a target population at an E : T of 5 : 1.

Results

Glioneurostem-like cells are effective targets of NK cells

Effective therapy for GBM will require the elimination of the radioresistant GSCs that are largely responsible for recurrence [23]. While tumour-associated antigen-specific T cells offer a highly selective therapeutic approach, antigen-independent effector cells, such as NK cells, have the potential to target and destroy GBM tumour cells that have a low neoantigen load.

We used three patient-derived GSC lines [24] shown to exhibit a stem cell-like expression profile and recapitulate high-grade gliomas in orthotopic xenograft mouse models [22,24] and performed cytotoxicity assays using peripheral blood-derived, IL-15-activated NK cells to confirm NK cell-mediated killing. Tumour cells differentiated from GSCs are more sensitive to NK cell killing than the GSC themselves [26], but GSCs are killed by NK cells in the presence of activating cytokines (Fig. 1a) [25]. We further tested whether NK cells activated with IL-15 would be efficient killers of GSCs, but retain specificity for GSCs over normal neural progenitor cells. We performed an NK cytotoxicity assay using a mixed target cell population comprised of tumour GSC cells and normal neural progenitor (NP) cells [22] at a ratio of 1 : 1. For all donors, IL-15-activated NK cells killed tumour cells in preference to the NP cells (Fig. 1b). These results suggest that, in short-term in-vitro cultures when sufficient immune cells are present and activated, GSCs are an effective and preferential target for NK cells.
Patient-derived NK cells exhibit an altered cell surface phenotype in GBM

The presence of infiltrating NK cells in GBM [11], coupled with their ability to recognize and kill GSCs (Fig. 1), suggests that they are rendered non-functional in the GBM tumour microenvironment. We performed flow cytometry-based analysis of intratumoural NK from GBM tissue and compared their surface phenotype to NK cells derived from autologous peripheral blood as well as blood from healthy donors. NK cell populations were defined as NKp46+ and CD3− due to high expression of CD56 (NCAM-1) on GBM tumour cells within the sample (Supporting information, Fig. S1). To confirm sampling of immune cells from within the GBM tumour tissue (and not from blood contamination of the tumour sample) we assayed the expression of PD-1 on T cells, and showed significantly enhanced expression of PD1 on tumour-derived T cells compared to their blood counterparts (Fig. 2a). Expression levels of NK cell surface molecules were similar on the blood-derived NK cells from four separate donors (coloured dots), with standard deviation from the mean.

Fig. 1. Natural killer (NK) cell-mediated killing of glioma stem-like cells. (a) NK cell cytotoxicity: cell tracker violet-labelled glioblastoma (GB) stem-like cell (GSC) lines (targets) were co-cultured with unlabelled, interleukin (IL)-15 activated NK cells (effectors) for 5 h at effector : target (E : T) ratios as shown. Co-cultures were then stained with a live/dead discriminator. The panel on the left shows identification of effector and target cells in the co-culture (for gating purposes) and the panels to the right show death of the labelled target cells at the different E : T ratios. The zero hour control is included as background cell death of the GSC cells. The three graphs summarize data obtained using three GSC lines (GBM1, GBM4 and GBM20) and three different NK cell donors (coloured dots), with standard deviation from the mean. (b) NK cell specificity: cytotoxicity assays of IL-15-activated NK cells co-cultured with a 1 : 1 mix of the GSC line (indicated) and neural progenitor cells (NP). The GSC and NP lines were labelled with different cell tracker dyes, allowing their fate in the assay to be determined separately. The flow cytometry plots show the percentage of dead GSC (here GBM4) and NP cells after zero and 5 h co-culture with NK cells. The graphs summarize these data for assays containing the three GSC lines using NK cells from four separate donors (coloured dots), with standard deviation from the mean.
Suppression of NK cells in glioblastoma

Collectively, GBM resident immune effector cells clearly demonstrate two separate phenotypes: the reduced expression of NK cell activation receptors and the increased expression of immune checkpoint molecules on T cells.

Surface antigen screening of GSCs identifies candidate immunomodulatory molecules

The GSC lines are selectively targeted by NK cells in vitro, but evade NK cells and other immune effector cells in vivo. To understand which immunomodulatory molecules expressed by GSC might be responsible for immune activation and inhibition, we analysed GSCs for the expression of cell surface immunomodulatory molecules. Using a flow cytometry-based screen, we identified 116 cell surface antigens expressed on four GSC lines lines (Supporting information, Table S1). Molecules detected on the GSCs included those associated with the cancer stem cell phenotype (CD24, CD44 and CD90) (Fig. 3a), as well as widely expressed cell surface molecules, such as major histocompatibility complex (MHC) class I (and β2-microglobulin), CD71 and CD98, as expected. Several immune inhibitory molecules were highly expressed, such as the immune checkpoint ligands programmed cell death ligand 1 (PD-L1) (CD274) and PD-L2 (CD273), providing a source for inhibition of PD-1 expressing T cells (Fig. 3a). In addition, we found expression of the ectonucleotidase CD73 that, together with CD39, generates extracellular adenosine to inhibit both NK cells and T cells via purinergic receptors [29], as well as expression of CD200 and CD47, modulators of myeloid cell activity (Fig. 3a).
Ligands of NK cell activation receptors, such as MICA/B (NKG2D ligand) and CD112 (a DNAM-1 ligand), as well as CD80 (a T cell co-stimulator), were detected, together with CD54 [intercellular adhesion molecule (ICAM)-1] and CD50 (ICAM-3); ligands of lymphocyte function-associated antigen 1 (LFA-1) required for NK cell and T cell-mediated cytotoxicity [30]. The GSC cell surface screen therefore revealed expression of a repertoire of targetable cell surface molecules with the potential to activate and inhibit NK cells, T cells and myeloid cells. This prompted us to explore the expression of immunosuppressive pathways in more detail, using a publicly available GBM single-cell gene expression data set [18]. Among 3589 single cells, we identified 757 co-expressing SOX2 and EGFR (defined by Darmanis et al. [18] as tumour cells) and 1527 cells expressing PTPRC (encoding CD45, a marker of cells of haematopoietic origin.) We next performed unsupervised hierarchical clustering using expression of lineage marker genes and genes encoding candidate immunosuppressive functions, which identified two main groups: non-immune (comprising tumour and neuronal cells) and immune cells (PTPRC+) (Fig. 3b). The immune cell group was dominated by expression of numerous myeloid cell markers (Fig. 3b). Genes encoding immunosuppressive functions were expressed within both the immune and non-immune clusters (Fig. 3b) and, overall, individual immune cells expressed a greater number of immunosuppressive genes than tumour cells (Supporting information, Fig. S3A). Consistent with the altered cell surface phenotype of GBM-resident NK cells (Fig. 2a), we found widespread expression of TGFβ family transcripts accounted for by TGFβ1 expression in the myeloid cells and TGFβ2 and TGFβ3 expression in non-immune cells. Furthermore, human leucocyte antigen G (HLA-G) (which plays a key role in regulating NK cell activity in pregnancy and cancer [31,32]) was also widely expressed. The HLA-G protein inhibits myeloid cells via receptors leucocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and LILRB2 [31], both of which were expressed in the immune compartment at the mRNA level. We identified strong expression of the receptor-ligand pair hepatitis A virus cellular receptor 1 (HAVCR1) (TIM3) and lectin, galactose binding, soluble 9 (LGALS9) in the myeloid cluster (92% of immune cells expressed HAVCR2 or LGALS9 and 60% expressed both genes; Supporting information, Fig. S3B). This scRNA-seq data along with the GSC surface antigen screen shows that both tumour and immune infiltrating cells express receptors and ligands that together constitute a complex network of immunosuppression. For example, the combined action of CD73 and CD39 generate immunosuppressive adenosine [29]; our data show expression of CD73 by the tumour cells.
(Fig. 3a) and 5′-nucleotidase ecto (NT5E) (encoding CD39) by the immune fraction (Fig. 3b), with Mohme et al. demonstrating CD39 expression by GBM-infiltrating T cells [13].

Furthermore, to assess whether this immunosuppressive network was induced in response to tumour, we analysed gene expression data derived from normal brain tissue [33] (Supporting information, Fig. S4). Microglia/macrophages (the only cell population in the normal brain expressing PTPRC/CD45) constitutively express several immunosuppressive genes, including immune checkpoints V-set immunoregulatory receptor (VSIR) and HAVCR2 and checkpoint ligands LGALS9, CD274 and PDCD1LG2. Some components of the immunosuppressive network found in brain tumours are therefore present in the healthy brain.

A spectrum of immune activity in GBM patients

We have previously used tumour transcriptome data to cluster melanoma patients according to their immune cell infiltrate [14]. This approach identified six CICs, with one cluster enriched in cytotoxic cells (CIC2) and another (CIC4) having low immune infiltrates and significantly worse survival [14]. We used this approach to classify GBM transcriptome data (from TCGA) and, like the situation in melanoma, the cohort of 154 patients clustered into the six CICs (Fig. 4a), with two main clusters CIC2 (high immune infiltrate) and CIC4 (low immune infiltrate). We found that CIC2 was significantly enriched for tumours of the mesenchymal subtype [34] (Supporting information, Table S2) that has been previously shown to have prolonged survival [21]. However, unlike melanoma [14], immune infiltration (reflected in the CIC clusters) was not associated with significant differences in survival in GBM (Supporting information, Fig. S5). There was also no significant difference in mutation burden, a surrogate of neoantigen load reflecting immunogenicity [8,9], between CIC2 and CIC4 in GBM (Fig. 4b). These data demonstrate that patients can be stratified based on the immune infiltrate but that, unlike melanoma, this stratification has no effect on patient outcomes under the conditions of treatment currently employed.

Immune activation induces feedback inhibitory pathways, including the expression of immune checkpoint molecules, and we therefore attempted to use the expression of genes in these pathways to understand the immune environment within the GBM CIC clusters. To do this we compared expression of anti-tumour effector functions and immunomodulatory genes in CIC2 and CIC4. Expression of the granzyme B (GZMB) and interferon (IFN)-γ genes were significantly higher in CIC2 than CIC4, consistent with the increased infiltration of cytotoxic T cells and NK cells (Fig. 4c). Furthermore, genes encoding immune checkpoint molecules (CTLA-4, PDCD1, HAVCR2, BTLA and VSIR), their ligands (PDCD1LG2, LGALS9) and forkhead box protein 3 (FoxP3) were also expressed at significantly higher levels in CIC2 than CIC4 (Fig. 4d), as were genes encoding soluble mediators of immunosuppression such IL-10, TGF-β1 and IDO1 (Fig. 4e). To confirm this we used microarray data from the REMBRANDT study [17] and GZMA gene expression as a simple surrogate for immune infiltration [35]. This analysis confirmed the significantly higher expression of multiple immunosuppressive functions in patients with increased expression of anti-tumour effector functions (Supporting information, Fig. S6). Collectively, these data drive our understanding of the GBM immune microenvironment, demonstrating a spectrum of immune infiltration, functionally compromised by an active immune-inhibitory network.

Discussion

Our analysis demonstrates tumour and immune-mediated immunosuppression within the GBM tumour microenvironment, functionally inactivating GBM anti-tumour immunity. We demonstrate reduced expression of tumour-sensing activating receptors on GBM-resident NK cells consistent with TGF-β activity [26]. The TGF-β family cytokines play a manifold role in glioma progression, including maintenance of the GSC pool, proliferation, invasion, angiogenesis and immunosuppression [36]. Multiple mechanisms of tumour-mediated down-regulation of NK cell activation receptors have been identified. However, we favour TGF-β as a modulator of the NK cell phenotype in GBM, as we show reduced expression of activation receptors coupled with increased expression of CD9, a tetraspanin induced by TGF-β in NK cells [28]. Mohme et al. showed that infiltrating T cells expressed PD-1, TIM-3 and CD39 [13], characteristic of T cell exhaustion [37]. Our analysis extended these findings by identifying CTLA-4 and LAG-3 on GBM-infiltrating T cells. Thus, GBM-infiltrating NK cells have reduced expression of activating receptors, whereas T cells have increased expression of immune checkpoint molecules, resulting in inhibition of both classes of cytotoxic lymphocytes. Furthermore, we identified CD73 on the GSC cell surface, and together with CD39 on infiltrating T cells these ectonucleosidases may act together to generate immunosuppressive adenosine which inhibits both NK cells and T cells [29]. Similar to Castriconi et al. [38], we demonstrate that activated NK cells are capable of recognizing and killing GSC cell lines in vitro, and we further show that NK cells discriminate between the GSC and a normal neural progenitor cell line.

The analysis of NK cells in GBM and their interaction with GSCs led to a more extensive analysis of the
GBM patients (TCGA; n=194)

**Signature:**
- Cytotoxic cells
- T cells
- Th17
- Treg
- DC
- aDC
- NK (CD56dim)
- Macrophage
- Neutrophil
- B cell
- CD8+ T cell
- Th1
- Th2
- Tfh
- Tem
- Treg
- pDC
- NK
- NK (CD56bright)
- Mast cell
- Eosinophil

(a)

(b)

(c)

(d)

(e)
immunosuppressive network. Our data highlight the abundance of immunosuppressive pathways operating in GBM. The most abundant immune cells in GBM belong to the myeloid lineage [12], and we show that GSCs express cell surface molecules such as PD-L1 and CD47, which inhibit phagocytosis by macrophage [18,39,40]. These data demonstrate that immune inhibition within GBM is mediated by both immune and non-immune lineages co-operating to provide a pro-tumour environment. Interestingly, CD47 and CD200 are important regulators of microglial activity and brain inflammation in non-malignant disease [41]. The single-cell transcriptome data reveal the extent of candidate pathways operating in GBM. Many of these molecules have been detected at the protein level on GBM tumour cells and immune infiltrates, both in this study using flow cytometry of GSCs and infiltrating lymphocytes (e.g. immune checkpoints, checkpoint ligands and ectonucleosidases), as well as in previous studies, using immunohistochemistry and flow cytometry [42–46].

Several of the immunosuppressive pathways evident in GBM are in place in the normal brain. In response to TGF-β, microglia suppress immunological activity and promote normal microglial functions such as synaptic pruning and neuronal growth support [47]. The expression of genes such as HAVCR2 and its ligand LGALS9 and CD274, together with TGFβ2 and IL-10, safeguard the normal brain against excessive inflammation [48]. Muller et al. demonstrate that infiltrating macrophages rather than resident microglia encode immunosuppressive cytokines within the GBM microenvironment [49]. Thus, immunosuppressive pathways operating in the GBM-free brain are utilized and extended upon by infiltrating myeloid cells, contributing to the extensive immunosuppressive network.

The identification of a spectrum of immune infiltration across the GBM cohort, accompanied by evidence of antitumour effector function and feedback inhibitory pathways, suggests that GBM should not simply be regarded as an immunogenically ‘cold’ tumour. The high expression of multiple feedback inhibitors, together with high expression of GZMB and IFN-γ in CIC2, identifies ongoing, or at least prior, immune activation in a subset of GBM patients, restrained by the action of these inhibitory pathways.

Indeed, melanoma shows interpatient heterogeneity of immune responses, and regarding melanoma as ‘hot’ fails to account for this variability. In melanoma, immune heterogeneity impacts upon survival [14] and the success of immunotherapy, with high expression of PD-1, CD8+ T cell infiltration and higher mutational burden associating with response to therapy [9]. We found no evidence for differential survival in GBM according to our CIC classifications, suggesting that the extensive immunosuppressive network removes any impact of immune control on GBM progression. However, these survival data are based on standard therapy and, by analogy with melanoma, we suggest that GBM CIC2 patients are more likely to respond to immunotherapy. Moreover, the extensive immunosuppressive network suggests that targeting multiple inhibitory pathways will be a probable requirement of GBM immunotherapy.

The mechanisms underlying interpatient heterogeneity of immune response in GBM are unclear [50]. β-catenin-mediated immune evasion pathways operate in CIC4, the group with the poorest prognosis in melanoma [14], whereas in this study we found no evidence of CTNNB1 differential expression between CIC2 and CIC4, nor was their mutational burden significantly different. However, GBM arises through various combinations of oncogene and tumour suppressor mutations, and several of these genes regulate tumour immune responses [51,52]. Thus, differences in oncogene and/or tumour suppressor gene mutations between patients is one potential factor underlying the spectrum of immune activity seen across the GBM cohort.

GSCs are effective targets of NK cells ex vivo, but GBM-infiltrating NK cells have a surface phenotype bearing the hallmarks of TGF-β-mediated immunosuppression. Further exploration of immunosuppressive pathways using gene and protein profiling indicated that both tumour and immune cell components contribute inhibitory factors. These pathways are a barrier to effective immunotherapy, but also represent candidate therapeutic targets. Combined checkpoint blockade is already outperforming monotherapy in melanoma [46]. Targeting combinations of the multiple immune checkpoints (PD-1, LAG-3, CTLA-4, TIM-3, VSIR/VISTA) or other immunosuppressive molecules (e.g. ectonucleosidases, TGF-B, IL-10) may prove beneficial in GBM. Strategies to activate NK cells in situ, e.g. via the use of oncolytic viruses [53–55] and methods to alter the immune composition of GBM, will also benefit from alleviating key immunosuppressive pathways. Importantly, GBM is not universally devoid of immune activity, and a subset
of patients with evidence of immune activity suggests that combinatorial immunotherapy would be most effective when patients are stratified according to immune infiltrates.

Acknowledgements
This work was supported by Cancer Research UK, The Brain Tumour Charity, Brain Tumor Research and Support across Yorkshire and the University of Leeds. We are indebted to those investigators who have made large data sets and analysis tools freely available for analysis. This work was supported by Cancer Research UK (C588/A19167, CC37059/A16369), The Brain Tumour Charity (13/192), Brain Tumor Research and Support across Yorkshire and the University of Leeds.

Disclosures
The authors declare that they have no competing interests.

Author contributions
Experimental design: H. J. C., E. B. W., G. P. C.; implementation: H. J. C., E. B. W. and J. N.; clinical support, including surgery and sample provision: S. C. S., A. A. M., R. K. M. and R. C.; analysis and interpretation of the data: H. J. C., E. B. W., G. P. C., L. F. S., J. N., A. D., H. W., J. N.-B., S. C. S. and A. A.; GSC provision: H. W.; informatics and statistical analyses: L. F. S., J. N., K. A. R., A. D. and G. P.C.; manuscript preparation: H. J.C., G. P. C. and E. B. W., with input from all authors.

References
1 deSouza RM, Shaweis H, Han C et al. Has the survival of patients with glioblastoma changed over the years? Br J Cancer 2016; 114:146–50.
2 Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15:422–42.
3 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017; 8:91779–94.
4 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74.
5 Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31:326–41.
6 Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486–99.
7 Charoentong P, Finotello F, Angelova M et al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18:248–62.
8 Schumacher TN, Schreiber RD.Neoantigens in cancer immunotherapy. Science 2015; 348:69–74.
9 McGranahan N, Furness AJ, Rosenthal R et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351:1463–9.
10 Feng L, Qian H, Yu X et al. Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme. Sci Rep 2017; 7:6968.
11 Kniecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol 2014; 116:1–9.
12 Gabrusiewicz K, Rodriguez B, Wei J et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 2016:1. https://doi.org/10.1172/jci.insight.85841.
13 Mohme M, Schlipfke S, Maire CL et al. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res 2018; 24:4187–200.
14 Nsengimana J, Laye J, Filia A et al. Beta-catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Invest 2018; 128:2048–63.
15 Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782–95.
16 Nsengimana J, Laye J, Filia A et al. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget 2015; 6:11683–93.
17 Gusev Y, Bhuvaneshwar K, Song L, Zenkluensen JC, Fine H, Madhavan S. The REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data 2018; 5:180158.
18 Darmanis S, Sloan SA, Croote D et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 2017; 21:1399–410.
19 Zhang Y, Sloan SA, Clarke LE et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 2016; 89:37–53.
20 Schroeter J, Reeker R, Suero Molina E et al. Glioma tissue obtained by modern ultrasonic aspiration with a simple sterile suction trap for primary cell culture and pathological evaluation. Eur Surg Res 2014; 53:37–42.
21 Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98–110.
22 Wurdak H, Zhu S, Romero A et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010; 6:37–47.
23 Jahan N, Lee JM, Shah K, Wakimoto H. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer 2017; 141:1671–81.
Polson ES, Kuchler VB, Abbosh C et al. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med 2018; 10:eaa2718.

Roy LO, Poirier MB, Fortin D. Differential expression and clinical significance of transforming growth factor-beta isoforms in GBM tumors. Int J Mol Sci 2018; 19:1113.

Wilson EB, El-Jawhari JJ, Neilson AL et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLOS ONE 2011; 6:e22842.

Viel S, Marcais A, Guimaraes FS et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 2016; 9:ra19.

Kesklin DB, Allan DS, Rybalov B et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16-NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 2007; 104:3378–83.

Kepp O, Loos F, Liu P, Kroemer G. Extracellular nucleosides and nucleotides as immunomodulators. Immuno Rev 2017; 280:83–92.

Campanero MR, Del Pozo MA, Arroyo AG et al. ICAM-3 interacts with LFA-1 and regulates the LFAA-ICAM-1 cell adhesion pathway. J Cell Biol 1993; 123:1007–16.

Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P et al. CD47-SIRPalpha signaling axis as an innate immune checkpoint. J Immunol 2009; 182:540–52.

Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint mechanisms. Nat Neurosci 2018; 21:779–86.

Klein RS, Hunter CA. Protective and pathological immunity during central nervous system infections. Immunology 2017; 46:891–909.

Muller S, Kohanbash G, Liu SJ et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol 2017; 18:234.

Chen Z, Hambardzumyan D. Immune microenvironment in glioblastoma subtypes. Front Immunol 2015; 6:234.

Wastowski IJ, Simoes RT, Yaghi L et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2’-deoxycytidine and interferon-gamma treatments: results from a multicentric study. Am J Pathol 2013; 182:540–52.

Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84–8.

El-Sherbiny YM, Holmes TD, Wetherill LF et al. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin Exp Immunol 2015; 180:98–107.

© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology, Clinical and Experimental Immunology, 200: 33–44
Rajani K, Parrish C, Kottke T et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 2016; 24:166–74.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher’s web site:

**Fig. S1.** Gating strategy for identification of T cells and NK cells in blood (top) and tumour (bottom) samples

**Fig. S2.** The cell surface phenotype of GBM-infiltrating lymphocytes

**Fig. S3.** Expression of immunomodulatory molecules in GBM single cell RNAseq data

**Fig. S4.** Gene expression in brain cell populations in the absence of tumour cells.

**Fig. S5.** Survival of GBM patients classified according to CIC

**Fig. S6.** Microarray data from 214 GBM patients in the REMBRANDT study

**Table S1.** Percentage expression of selected antigen expressed on the surface of human GBM stem-like cells GBM4, GBM11 and GBM13

**Table S2.** The number of TCGA patient tumours classified into each GBM expression subtype per immune group